68 Ga-PSMA

Published on Jan 1, 2020
· DOI :10.1007/978-3-030-27779-6_12
Robert Pichler2
Estimated H-index: 2
(University of Graz),
Johannes Wolfsgruber2
Estimated H-index: 2
(Steyr Mannlicher)
+ 2 AuthorsAndreas Dunzinger4
Estimated H-index: 4
Imaging prostate cancer and metastases either by morphologic radiological approach or nuclear medicine methods has not fulfilled the expectations of the clinicians until several years. PSMA—prostate-specific membrane antigen—which can be labeled with positron-emitting isotopes mostly 68Ga—changed this setting substantially. Prostate cancer is the most common tumor entity in men worldwide and the third leading cause of cancer-related death in men in Europe and the USA. Biochemical relapse is a frequent event after primary therapy. A large body of evidence is available for restaging of prostate cancer patients with biochemical recurrence. 68Ga-PSMA PET/CT demonstrates high detection rates in patients with biochemical recurrence of prostate cancer after primary radiation therapy as well as after radical prostatectomy. 68Ga-PSMA PET has also been used for radiotherapy planning. Compared to conventional CT, PSMA PET/CT had a remarkable impact on radiotherapeutic approach especially in postoperative patients. PSMA is an ideal structure for both imaging and targeted therapy for prostate cancer, therefore enabling a theranostic approach.
📖 Papers frequently viewed together
8 Citations
#1Marlon Perera (UQ: University of Queensland)H-Index: 21
#2Nathan Papa (University of Melbourne)H-Index: 13
Last. Declan G. Murphy (University of Melbourne)H-Index: 107
view all 11 authors...
Abstract Context Accurate staging of high-risk localised, advanced, and metastatic prostate cancer is becoming increasingly more important in guiding local and systemic treatment. Gallium-68 prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has increasingly been utilised globally to assess the local and metastatic burden of prostate cancer, typically in biochemically recurrent or advanced disease. Following our previous meta-analysis, a high-volume series has been repo...
251 CitationsSource
#1Julian Müller (UZH: University of Zurich)H-Index: 12
#2Daniela A. Ferraro (UZH: University of Zurich)H-Index: 8
Last. Irene A. Burger (UZH: University of Zurich)H-Index: 26
view all 18 authors...
Purpose The fast-increasing use of positron emission tomography (PET) with prostate-specific membrane antigen (PSMA) ligand for the imaging of prostate cancer (PCA) biochemical recurrence has led to a rapid change in treatment concepts. Since the superiority of 68Ga-PSMA-11 PET in detecting recurrent PCA is well established, the aim of our study was to assess its effect on management and outcome in all patients imaged during the first year after its introduction into clinical routine.
26 CitationsSource
#1Joseph R. EnglandH-Index: 4
#2Jeremy PaluchH-Index: 5
Last. Hossein JadvarH-Index: 40
view all 4 authors...
PURPOSE: The aims of this study were to report on our initial experience using F-fluciclovine PET/CT to detect recurrent prostate carcinoma in patients with low serum prostate-specific antigen (PSA) after definitive treatment of primary disease and to conduct a preliminary investigation for factors associated with positive scan findings. PATIENTS AND METHODS: In this retrospective study, F-fluciclovine PET/CT scans from 28 men with suspected recurrence of prostate carcinoma and PSA values of 1 n...
17 CitationsSource
#1Stefan A. Koerber (DKFZ: German Cancer Research Center)H-Index: 12
#2Leon Will (University Hospital Heidelberg)H-Index: 6
Last. Frederik L. Giesel (DKFZ: German Cancer Research Center)H-Index: 60
view all 14 authors...
: The present study analyzed the impact of Gallium-68 (68Ga)-labeled prostate-specific membrane antigen-HBED-CC (68Ga-PSMA-11) positron-emission tomography (PET)/computed tomography (CT) on radiotherapeutic management in a large cohort of men with primary or recurrent disease. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68Ga-PSMA-11 PET/CT as well as conventional imaging. 50 patients were treatment naive, 11 had persistent prostate-specific antigen (PSA)...
34 CitationsSource
#1Mikhail Kesler (Tel Aviv Sourasky Medical Center)H-Index: 3
#2Charles D. Levine (Tel Aviv Sourasky Medical Center)H-Index: 11
Last. Einat Even-Sapir (Tel Aviv Sourasky Medical Center)H-Index: 44
view all 9 authors...
: Background:68Ga-Prostate Specific Membrane Antigen (68Ga-PSMA), a positron emission tomography (PET) tracer that was recently introduce for imaging of prostate cancer, may accumulate in other solid tumors including Hepatocellular Carcinoma (HCC). The aim of the study was to assess the potential role of 68Ga-PSMA PET-Computed Tomography (CT) for imaging of HCC. Material and Methods: A prospective pilot study in seven patients with HCC with 41 liver lesions: 37 suspected malignant lesions (tumor...
40 CitationsSource
#1Gerald L. Andriole (WashU: Washington University in St. Louis)H-Index: 97
#2Lale Kostakoglu (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 56
Last. Barry A. Siegel (WashU: Washington University in St. Louis)H-Index: 103
view all 8 authors...
Purpose:The prospective, multicenter LOCATE (18F Fluciclovine [FACBC] PET/CT in Patients with Rising PSA after Initial Prostate Cancer Treatment) trial assessed the impact of positron emission tomography/computerized tomography with 18F-fluciclovine on treatment plans in patients with biochemical recurrence of prostate cancer after primary therapy with curative intent.Materials and Methods:Men who had undergone curative intent treatment of histologically confirmed prostate cancer but who were su...
61 CitationsSource
#1Alexander Heinzel (RWTH Aachen University)H-Index: 29
#2Dima Boghos (RWTH Aachen University)H-Index: 1
Last. Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
view all 7 authors...
Purpose To evaluate the use of 68Ga-PSMA PET/CT for monitoring response to 177Lu-617 PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC).
28 CitationsSource
#1Mike Sathekge (University of Pretoria)H-Index: 29
Last. Alfred Morgenstern (University of Pretoria)H-Index: 45
view all 11 authors...
Background A remarkable therapeutic efficacy has been demonstrated with 225Ac-prostate-specific membrane antigen (PSMA)-617 in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients. We report our experience with 225Ac-PSMA-617 therapy in chemotherapy-naive patients with advanced metastatic prostate carcinoma.
131 CitationsSource
#1Bernhard Grubmüller (Medical University of Vienna)H-Index: 12
#2Pascal A. T. Baltzer (Medical University of Vienna)H-Index: 42
Last. Markus Hartenbach (Medical University of Vienna)H-Index: 15
view all 22 authors...
Purpose: Primary staging of prostate cancer relies on modalities, which are limited. We evaluate simultaneous [ 68 Ga]Ga-PSMA-11 PET (PSMA-PET)/MRI as a new diagnostic method for primary tumor–node–metastasis staging compared with histology and its impact on therapeutic decisions. Patients and Methods: We investigated 122 patients with PSMA-PET/MRI prior to planned radical prostatectomy (RP). Primary endpoint was the accuracy of PSMA-PET/MRI in tumor staging as compared with staging-relevant his...
51 CitationsSource
#1Kareem Rayn (NIH: National Institutes of Health)H-Index: 8
#2Youssef A Elnabawi (Tufts University)H-Index: 1
Last. Niki Sheth (SUNY Downstate Medical Center)H-Index: 4
view all 3 authors...
Several imaging modalities exist for the investigation of prostate cancer (PCa). From ultrasound to computed tomography (CT) and magnetic resonance imaging (MRI), the role of imaging in detecting lesion foci, staging, and localizing disease after biochemical recurrence (BCR) is expanding. However, many of the conventional imaging modalities are suboptimal, particularly in the detection of metastasis. Positron emission tomography (PET) has recently emerged as a promising tool in PCa management. T...
14 CitationsSource
Cited By0